Gainers

• China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million.
• Neogen (NASDAQ:NEOG) shares rose 8.88% to $13.02. The company's market cap stands at $2.8 billion. The company's, Q1 earnings came out today.
• Calidi Biotherapeutics (AMEX:CLDI) stock increased by 7.45% to $1.1. The company's market cap stands at $2.7 million.
• Aldeyra Therapeutics (NASDAQ:ALDX) shares increased by 6.99% to $0.98. The company's market cap stands at $55.7 million.
• Sunshine Biopharma (NASDAQ:SBFM) shares increased by 6.81% to $0.42. The company's market cap stands at $1.6 million.
• Azitra (AMEX:AZTR) shares moved upwards by 6.15% to $0.14. The market value of their outstanding shares is at $8.2 million.

Losers

• Caribou Biosciences (NASDAQ:CRBU) shares fell 46.3% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $127.5 million.
• Actuate Therapeutics (NASDAQ:ACTU) stock fell 13.76% to $0.7. The market value of their outstanding shares is at $21.0 million.
• Jupiter Neurosciences (NASDAQ:JUNS) shares declined by 8.4% to $2.62. The market value of their outstanding shares is at $3.1 million.
• Modular Medical (NASDAQ:MODD) stock declined by 7.33% to $2.53. The market value of their outstanding shares is at $18.7 million.
• Kairos Pharma (AMEX:KAPA) stock decreased by 6.96% to $1.07. The company's market cap stands at $5.2 million.
• SILO Pharma (NASDAQ:SILO) stock declined by 5.52% to $1.37. The company's market cap stands at $3.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.